[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638170":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":37,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":25},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Dose Group","ACTIVE_COMPARATOR","Participants receive standard-dose trimethoprim-sulfamethoxazole (TMP-SMX) 80\u002F400 mg once daily for 12 consecutive months for the prevention of Pneumocystis jirovecii pneumonia (PJP) after kidney transplantation.",[13],"Drug: Trimethoprim-Sulfamethoxazole (TMP-SMX)",{"label":15,"type":16,"description":17,"interventionNames":18},"Low Dose Group","EXPERIMENTAL","Participants receive trimethoprim-sulfamethoxazole (TMP-SMX) 40\u002F200 mg (half tablet) once daily for 12 consecutive months for the prevention of Pneumocystis jirovecii pneumonia (PJP) after kidney transplantation.",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Trimethoprim-Sulfamethoxazole (TMP-SMX)","80\u002F400 mg orally once daily for 12 consecutive months for the prophylaxis",[9],null,{"type":21,"name":22,"description":27,"armGroupLabels":28,"otherNames":25},"40\u002F200 mg orally once daily for 12 consecutive months for the prophylaxis",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Xuqin jiang","CONTACT","+86-13675605989","xqjiang@ustc.edu.cn",{"type":36,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[38,41],{"name":39,"class":40},"The First Affiliated Hospital of Anhui Medical University","OTHER",{"name":42,"class":40},"The Second Hospital of Anhui Medical University","100638170","phase-4-low--vs-standard-dose-tmp-smx-for-prevention-of-pneumocystis-pneumonia-after-kidney-transplantation-100638170",false,"NCT07619027","Low- vs Standard-Dose TMP-SMX for Prevention of Pneumocystis Pneumonia After Kidney Transplantation","A Prospective Randomized Controlled Study of Low-Dose Versus Standard-Dose Trimethoprim-Sulfamethoxazole for the Prevention of Pneumocystis Jirovecii Pneumonia After Kidney Transplantation","TMP-SMX PJP","Inclusion Criteria:\n\n-Age: Between 18 and 70 years old. Transplant Status: Recipients of a first-time kidney transplant. Renal Function: Serum creatinine levels have stabilized with a creatinine -----clearance (CrCl) \\> 30 mL\u002Fmin.\n\nConsent \\& Compliance: Voluntarily agree to participate in this study, are capable of cooperating with the investigators, and have signed the informed consent form.\n\nExclusion Criteria:\n\n-HIV Infection: Known HIV positive status. Drug Allergy: History of allergy or hypersensitivity to TMP-SMX (Trimethoprim-Sulfamethoxazole).\n\nPrior PJP: History of Pneumocystis jirovecii pneumonia (PJP) before transplantation.\n\nG6PD Deficiency: Glucose-6-phosphate dehydrogenase deficiency. Multi-organ Transplant: Recipients of multi-organ transplants. Active Infection: Presence of other severe concurrent infections. Immune System Disorders: Concomitant diseases affecting the immune system (e.g., malignancies\u002Ftumors, connective tissue diseases, hematological system diseases).\n\nPregnancy: Pregnant women. Anemia: Megaloblastic anemia. Non-compliance: Inability to adhere to regular follow-up schedules or poor compliance.","ALL","18 Years","70 Years",{"count":55,"type":56},1084,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","This study is a prospective randomized controlled trial designed to evaluate the efficacy and safety of low-dose versus standard-dose trimethoprim-sulfamethoxazole (TMP-SMX) for the prevention of Pneumocystis jirovecii pneumonia (PJP) in kidney transplant recipients.\n\nParticipants will be randomly assigned to receive either low-dose or standard-dose TMP-SMX for 12 months after kidney transplantation. The primary outcome is the incidence of PJP during the prophylaxis period. Secondary outcomes include adverse events related to TMP-SMX, dose reduction or discontinuation rates, incidence and timing of PJP after discontinuation, and other post-transplant complications.\n\nParticipants will be followed for a total of 24 months, including a 12-month prophylaxis period and an additional 12-month follow-up period after discontinuation. This study aims to provide evidence for optimizing prophylactic strategies against PJP in kidney transplant recipients.",[62,63],"Pneumocystis Jirovecii Pneumonia","Kidney Transplantation",[65,66,67,68],"PJP prophylaxis","Kidney transplant recipients","Trimethoprim-Sulfamethoxazole","Low-dose","NOT_YET_RECRUITING","2026-05-26",{"date":72,"type":73},"2026-06-01","ACTUAL",{"date":75,"type":56},"2026-06",{"date":77,"type":56},"2030-06",{"name":5,"class":6}]